Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Over-encapsulated tablets containing active drug substance administered PO.”In the company’s words, NCT07089875 on ClinicalTrials.gov
- Tested for
- Gout (2 trials), Tophaceous Gout
- Main trialPhase 3
- “The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.”In the company’s words, NCT07089875 on ClinicalTrials.gov
Other drugs for Gout
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SSGJ-6133SBio · Phase 2
- PRX-115Protalix · Phase 2
- BR2251BioRay Pharmaceutical Co., Ltd. · Phase 2
Coming up3
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 29 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 29 Nov 2027 | A Study of Dotinurad Versus Allopurinol in Participants With Gout | |
| Phase 3Recruiting | 31 Dec 2027 | A Study of Dotinurad Versus Allopurinol in Tophaceous Gout | |
| Phase 2Recruiting | Jul 2027 | A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026